undamentalytics Newsletter
Sign in

Viridian Therapeutics, Inc.\de revenue

Viridian Therapeutics, Inc.\de's revenue was $70.8m in fiscal 2025, up 23359.9% on the year before. Since fiscal 2013 ($5.5m) it has grown at a compound 23.8% a year. Over the last twelve months it was $71.1m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue5663484132007171
Growth on the year before—+18.1%−12.0%−39.1%+15.1%+109.5%−46.8%−76.5%+182.2%−40.2%−82.3%−3.8%+>999%—
Gross profit3331——————————
Gross margin49.4%48.1%56.7%26.7%——————————

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Licenses $70M 98.8% —
Collaboration $849,000 1.2% ▲ 181.1%

From Viridian Therapeutics, Inc.\de's 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Viridian Therapeutics, Inc.\de $71.1m 23220.3% 264.4%
Wave Life Sciences, Inc. $70.9m 202.3% 20.7%
Compugen LTD $72.8m 161.1% 302.6%
Recursion Pharmaceuticals, Inc. $68.2m 56.2% 12.9%
Cytokinetics Inc $67.7m -21.1% 89.5%
Assembly Biosciences, Inc. $74.8m 125.1% -3.3%

Compare with peers

Head to head: VRDN vs WVECGEN vs VRDNRXRX vs VRDNASMB vs VRDN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Viridian Therapeutics, Inc.\de's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Viridian Therapeutics, Inc.\de.